AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $41.45.

ANAB has been the subject of a number of research reports. HC Wainwright lowered AnaptysBio from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $52.00 to $19.00 in a research report on Wednesday, December 11th. UBS Group lifted their price target on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Wells Fargo & Company dropped their price objective on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. JPMorgan Chase & Co. decreased their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Finally, BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd.

AnaptysBio Trading Up 9.3 %

Shares of AnaptysBio stock opened at $14.60 on Monday. The company’s 50-day moving average price is $19.75 and its two-hundred day moving average price is $28.47. AnaptysBio has a 52 week low of $12.51 and a 52 week high of $41.31. The stock has a market cap of $444.26 million, a PE ratio of -2.40 and a beta of -0.02.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. On average, equities analysts predict that AnaptysBio will post -6.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Ecor1 Capital, Llc acquired 65,184 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were bought at an average price of $12.92 per share, with a total value of $842,177.28. Following the acquisition, the director now owns 7,860,180 shares of the company’s stock, valued at $101,553,525.60. This trade represents a 0.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Several institutional investors have recently modified their holdings of ANAB. Frazier Life Sciences Management L.P. boosted its stake in AnaptysBio by 2.0% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after buying an additional 43,598 shares in the last quarter. Ensign Peak Advisors Inc raised its position in shares of AnaptysBio by 74.4% during the second quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock worth $1,898,000 after acquiring an additional 32,313 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of AnaptysBio by 202.8% during the third quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock worth $1,816,000 after acquiring an additional 36,300 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of AnaptysBio by 677.9% during the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after acquiring an additional 168,813 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.